Alloy Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
121
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$41.7M
- Investors
-
19
Alloy Therapeutics General Information
Description
Developer of drug discovery platform designed to promote and facilitate antibody discovery projects. The company has developed humanized transgenic antibody discovery technology which provides broad, non-exclusive access to drug discovery tools, enabling scientists to work on their antibody projects in a hassle-free manner.
Contact Information
Website
www.alloytx.comCorporate Office
- 275 Second Avenue
- Suite 200
- Waltham, MA 02451
- United States
Corporate Office
- 275 Second Avenue
- Suite 200
- Waltham, MA 02451
- United States
Alloy Therapeutics Timeline
Alloy Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series D) | 16-Sep-2022 | $41.7M | Completed | Generating Revenue | ||
| 4. Grant | 01-Jun-2021 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 02-Apr-2021 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 10-May-2020 | $11.2M | $17.2M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A1) | 15-May-2019 | $6M | $6M | Completed | Generating Revenue |
Alloy Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A3 | ||||||||
| Series A2 | 1,949,906 | $0.000100 | $0.77 | $0.77 | 1x | $0.77 | 5.21% | |
| Series A1 | 1,444,374 | $0.000100 | $0.35 | $0.35 | 1x | $0.35 | 3.86% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Alloy Therapeutics Comparisons
Industry
Financing
Details
Alloy Therapeutics Competitors (20)
One of Alloy Therapeutics’s 20 competitors is PhoreMost, a Venture Capital-Backed company based in Pampisford, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| PhoreMost | Venture Capital-Backed | Pampisford, United Kingdom | ||||
| Ablexis | Venture Capital-Backed | San Diego, CA | ||||
| Integral Molecular | Private Debt Financed | Philadelphia, PA | ||||
| Noble Life Sciences | Venture Capital-Backed | Sykesville, MD | ||||
| Abveris | Formerly VC-backed | Quincy, MA |
Alloy Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Alloy Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Alloy Therapeutics Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| OurCrowd | Venture Capital | Minority | ||
| Massachusetts Life Sciences Center | Government | |||
| 10X Capital | Venture Capital | Minority | ||
| Calm Ventures | Venture Capital | Minority | ||
| Founders Fund | Venture Capital | Minority |
Alloy Therapeutics Investments & Acquisitions (13)
Alloy Therapeutics’s most recent deal was a Later Stage VC with Wheeler Bio for . The deal was made on 20-Mar-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Wheeler Bio | 20-Mar-2025 | Later Stage VC | Biotechnology | ||
| Aakha Biologics | 15-Apr-2024 | Seed Round | Biotechnology | ||
| Cantai Therapeutics | 20-Nov-2023 | Seed Round | Therapeutic Devices | ||
| Vernal Biosciences | 14-Jun-2023 | Early Stage VC | Biotechnology | ||
| Wheeler Bio | 18-May-2023 | Early Stage VC | Biotechnology |
Alloy Therapeutics Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| deepCDR | Basel, Switzerland | 2019 | |
| Lanier Biotherapeutics | Jefferson, GA | 2000 | |
| 82VS | Boston, MA |
Alloy Therapeutics FAQs
-
When was Alloy Therapeutics founded?
Alloy Therapeutics was founded in 2017.
-
Where is Alloy Therapeutics headquartered?
Alloy Therapeutics is headquartered in Waltham, MA.
-
What is the size of Alloy Therapeutics?
Alloy Therapeutics has 121 total employees.
-
What industry is Alloy Therapeutics in?
Alloy Therapeutics’s primary industry is Discovery Tools (Healthcare).
-
Is Alloy Therapeutics a private or public company?
Alloy Therapeutics is a Private company.
-
What is the current valuation of Alloy Therapeutics?
The current valuation of Alloy Therapeutics is .
-
What is Alloy Therapeutics’s current revenue?
The current revenue for Alloy Therapeutics is .
-
How much funding has Alloy Therapeutics raised over time?
Alloy Therapeutics has raised $134M.
-
Who are Alloy Therapeutics’s investors?
OurCrowd, Massachusetts Life Sciences Center, 10X Capital, Calm Ventures, and Founders Fund are 5 of 19 investors who have invested in Alloy Therapeutics.
-
Who are Alloy Therapeutics’s competitors?
PhoreMost, Ablexis, Integral Molecular, Noble Life Sciences, and Abveris are some of the 20 competitors of Alloy Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
